The partners of Smart & Biggar/Fetherstonhaugh are pleased to announce that Jonas Gifford, Martin Tremblay, and Ekaterina Tsimberis have joined our partnership and that David Walters has been elevated to the position of Counsel in our firm.
Smart & Biggar is pleased to welcome the following associates to our firm:
Smart & Biggar is pleased to announce that David Schwartz, a partner in our Ottawa office, has been named the 2016 Biotechnology Law "Lawyer of the Year" in Ottawa by Best Lawyers.
Smart & Biggar/Fetherstonaugh is pleased to announce that John Bochnovic has been appointed as the Executive Director for AIPPI, effective September 1, 2015. John will be based in Zurich at the General Secretariat of AIPPI.
Smart & Biggar wishes to extend a warm welcome to our Toronto office's newest patent agent, Shahrzad Esmaili. Shahrzad Esmaili has over 10 years of experience in intellectual property law. She graduated from the University of Toronto with a B.Sc. in Electrical Engineering, and from Ryerson University with a M.Eng.
by Artemis Lai
On June 24, 2016, the much anticipated amendments to the Patent Act and Trademarks Act recognizing patent agent privilege and trademark agent privilege will come into force.
by Andrea Kroetch
The Competition Bureau has taken action against Canadian outerwear company Moose Knuckles for allegedly falsely claiming that their premium winter jackets are “Made in Canada”. In the application filed with Competition Tribunal, the Bureau claims that the company has engaged in deceptive mark
by Abigail Smith On May 31, 2016, the Federal Court of Appeal set aside a decision of the Federal Court awarding Teva damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations) in relation to its venlafaxine hydrochloride product (Pfizer’s Effexor XR) on the basis
by Kevin Siu The Federal Court on May 31, 2016 issued its public judgment in Janssen Inc v Teva Canada Ltd, 2016 FC 593, for the quantification of damages arising from infringement of Daiichi Sankyo’s Patent No. 1,304,080 for levofloxacin (LEVAQUIN). In the earlier liability phase of the action, Teva (then Novo
by David Schwartz and Tomek Nishijima
On June 6, 2016, the Canadian Intellectual Property Office (CIPO) released consultation documents concerning trademark fees and patent fees, which set out its proposed fee changes resulting from the amendments to the Canadian Trademarks Act and Patent Act. The deadline to s
Smart & Biggar is honoured to be once again recognized as one of only two Canadian firms selected as a ‘Band One’ firm in Canadian intellectual property law — the highest ranking given to firms by the directory.
One of only two Canadian firms to be recognized as a Gold band status in the category of litigation, transactions and prosecution, our professionals were lauded as being “the highest quality and intelligent, business orientated and hardworking”.
We are pleased to announce that Nancy Pei is one of only seven women in Canada chosen as one of the Top 250 Women in IP by Managing Intellectual Property’s IP Stars list of the Top 250 Women in IP for 2016.
World IP Review Leaders is a new, comprehensive guide to the top intellectual property lawyers in the areas of patents and trademarks across the globe. We are delighted to announce that ten members of the Smart & Biggar team have been included in this guide: Christian Bolduc Mark Evans Ronald Faggetter
Smart & Biggar/Fetherstonhaugh is proud to have been recognized with two prestigious awards by the UK publication Managing Intellectual Property (MIP). The firm was chosen as the 2016 Canadian Specialty IP Firm of the Year and as the Canadian Trademark Contentious Firm of the Year. The awards were presented at MIP